CardieX Limited announced the key changes to its executive team and appointments: Former Masimo Inc. Executive Joins as Director of Corporate Development. Mr. ZiHan Lin has been appointed Director of Corporate Development of CardieX. Mr. Lin was formerly the Director of North Asia for Masimo, Inc, where he focused on the Chinese and Asian strategy for Masimo's portfolio of devices.

Mr. Lin will be focusing on expanding the opportunity for CardieX's products in the Chinese market as well as accelerating the commercialization of CardieX's cardiovascular technologies into new devices and technologies. Mr. Lin will report directly to the CEO. Former Johnson & Johnson Executive Joins Company Advisory Board: Ms. Rhona Welch also joins CardieX as a member of the company's Advisory Board which will expand with appropriate and experienced industry executives to lend support to the Board and Management.

Ms. Welch will be working closely with the company's executive team in the development of new opportunities and business strategy with respect to the expansion of CardieX's technologies and reimbursement programs. Ms. Welch is a 20-year veteran of the US healthcare industry and was a former Director of Health Policy Reimbursement at Johnson & Johnson. Her expertise includes new medical device reimbursement assessment and strategy, development of value propositions targeted to payers and health administration, integration of economic value into the product development process, and field training in the changing healthcare environment. Mr. Doug Kurschinski has been promoted to Executive Vice President and Head of Global Sales of CardieX's AtCor Medical division.

Mr. Kurschinski was previously Senior Vice President and General Manager of AtCor Medical where he led the US sales team. Mr. Kurschinski will head the AtCor cardiovascular division as well as the global sales team supporting that operation. Commensurate with Mr. Kurschinski's new role, former company CEO Duncan Ross has left the company effective 1 July 2018.